problems with glp-1 drugs Long-term Success of GLP-1s Hinges on More Than Just a Prescription Focus on GLP-1 drugs &

Silico docking (Schrodinger Inc., Small-Molecule Drug Discovery Suite, 2016-1) revealed that benserazide binds to the active site of CBS (PDB ID: 1JBQ) and reacts with the PLP cofactor to form a reversible but kinetically stable Schiff base, and its trihydroxybenzyl ring can form hydrogen bonds with polar residues located in the peripheral cavity (such as His203, Tyr223, and Tyr308), resulting in strong inhibition

Every batch is third-party HPLC-tested to 99% purity, with a certificate of analysis (COA) available on request and US-based cold-chain handling

10.1038/s41598-024-56818-4 Sci Rep

GHK-Cu dosage in clinical and research contexts typically ranges from 0.5 to 3 mg administered monthly via subcutaneous injection, though individual protocols vary based on treatment goals and baseline health markers

Tissue distribution and biological functions beyond glucose metabolism: 2.2.1